ACR 20 Response

ACR 20 Response

A measure—based on American College of Rheumatology criteria—of at least a 20% improvement in the number of tender and swollen joints, and a 20% improvement in at least 3 of the following: the patient’s global assessment of disease status; the patient’s assessment of pain; the patient’s assessment of function—measured using the Stanford Health Assessment Questionnaire; the physician’s global assessment of disease status; serum C-reactive protein levels.
References in periodicals archive ?
INDIANAPOLIS, April 20, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the investigational medicine ixekizumab was statistically superior to placebo in the treatment of patients with active psoriatic arthritis (PsA), as demonstrated by the proportion of patients achieving an ACR 20 response.
Otezla treatment with or without concomitant Dmards, compared with placebo with or without concomitant Dmards, resulted in greater improvement in the signs and symptoms of psoriatic arthritis, as demonstrated by the proportion of patients with an ACR 20 response at week 16.
The primary endpoints were ACR 20 response rate at 6 months, change in HAQ and change in mTSS at week 52.
In a phase 2 placebo-controlled study exploring the effect of several doses of IV abatacept in 170 patients with PsA, ACR 20 response was achieved by 48% of those receiving the RA-labeled dose of 10 mg/kg at 6 months.
The primary efficacy endpoint of this study is to determine the percent of patients with ACR 20 response at the end of 12 weeks.
An ACR 20 response is defined as a reduction of at least 20% in the number of tender and swollen joints plus an improvement of at least 20% in at least three of the following five criteria: patient's assessment of pain, patient's assessment of disease activity, physician's assessment of disease activity, patient's assessment of physical function, and serum C-reactive protein concentration.
The primary endpoint will be the rate of ACR 20 response at week 26.
Of 28 patients treated with this interleukin 1 receptor antagonist after failing a TNF blocker, only 8% achieved an ACR 20 response, and no patients achieved an ACR 50 or ACR 70 response, she said.
The primary endpoint of ACQUIRE was to determine non-inferiority of ORENCIA SC plus methotrexate (MTX) to ORENCIA IV plus MTX by difference in ACR 20 response at 6 months.
At 3 months, patients achieving an ACR 20 response 59.
42 percent and 50 percent of patients receiving ustekinumab 45 mg and 90 mg, respectively, achieved at least an ACR 20 response compared with 23 percent of patients receiving placebo (P < 0.